All News
Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain
A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and barriers to conducting research due to existing federal and state regulations.
Read Article
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis
Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs.
Read Article
Trends in Rheumatoid Arthritis Disabililty, Despite Biologics
Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.
Read Article
$30 Billion and Counting (4.29.2022)
Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.
Read Article
Biologics for JIA? Not So Fast, Say Insurers
It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.
Read Article
Arthritis Predicts Hepatic Fibrosis in Hemochromatosis
Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis.
Read Article
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients
Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).
Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102 countries was analyzed.
Evusheld as Protective Therapy in High Risk COVID-19 Patients
A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
